Source comparison
BPC-157 Help TBI Research: Full Comparison
The table below compares BPC-157's preclinical TBI profile against established neuroprotective candidates that have undergone human testing. BPC-157 VEGF upregulation, BBB stabilization, cytokine modulation 30–50% lesion reduction, improved functional scores i
This comparison does not assign a generated winner or score.
- The table below compares BPC-157's preclinical TBI profile against established neuroprotective candidates that have undergone human testing.
- BPC-157
- VEGF upregulation, BBB stabilization, cytokine modulation
- 30–50% lesion reduction, improved functional scores in rodent models
- Zero registered trials; no Phase I data
- No human pharmacokinetics, no dosing data, no safety profile in TBI populations
- Promising preclinical signal but unproven in humans; translational gap unaddressed as of 2026
- Progesterone
- Anti-inflammatory, membrane stabilization, reduced edema
- Strong rodent efficacy across multiple TBI models
- PROTECT III trial (2014): no benefit vs placebo in moderate-severe TBI
- Dosing window critical; benefit lost if started >8 hours post-injury
- Failed despite strong animal data. Highlights species translation risk
- Citicoline
- Membrane phospholipid precursor, cholinergic support
- Reduced contusion volume, improved cognitive outcomes in rodent studies
- COBRIT trial (2012): no benefit in mild-moderate TBI
- Heterogeneous injury types diluted treatment effect
- Another strong preclinical candidate with null human results
- Hypothermia
- Metabolic suppression, reduced excitotoxicity
- Consistent neuroprotection across species and injury models
- Proven benefit in cardiac arrest; mixed results in isolated TBI
- Requires rapid induction; logistical barriers in field settings
- Gold standard neuroprotection but operationally complex
- Mannitol
- Osmotic diuresis, intracranial pressure reduction
- Not tested in animal TBI models (used clinically based on mechanism)
- Standard of care for elevated ICP in severe TBI
- Symptomatic treatment only; does not modify injury cascade
- Addresses consequences, not pathophysiology